Table 1. Baseline characteristics.
| Cohort 1 (n=26) | Cohort 2 (n=25) | |
|---|---|---|
| Sex | ||
| Male | 15 (58%) | 13 (52%) |
| Female | 11 (42%) | 12 (48%) |
|
| ||
| Race | ||
| White | 24 (92%) | 20 (80%) |
| Other | 2 (8%) | 5 (20%) |
|
| ||
| Ethnic origin | ||
| Hispanic or Latino | 4 (15%) | 3 (12%) |
| Other | 22 (85%) | 22 (88%) |
|
| ||
| Age (years) | 67 (55–74) | 65 (58–71) |
| <65 | 12 (46%) | 12 (48%) |
| ≥65 | 14 (54%) | 13 (52%) |
|
| ||
| Local recurrent or unresectable cancer | 3 (12%) | 2 (8%) |
|
| ||
| Metastatic cancer | 23 (88%) | 23 (92%) |
|
| ||
| ECOG performance score | ||
| 0 | 15 (58%) | 13 (52%) |
| 1 | 11 (42%) | 12 (48%) |
|
| ||
| Previous treatments | ||
| 0 | 19 (73%) | 0 |
| 1 | 4 (15%) | 7 (28%) |
| 2 | 2 (8%) | 9 (36%) |
| ≥3 | 1 (4%) | 9 (36%) |
Data are number of patients (%) or median (IQR). Cohort 1 includes patients who had not previously received a multikinase inhibitor and cohort 2 includes those previously treated with a multikinase inhibitor. ECOG=Eastern Cooperative Oncology Group.